OrthoPediatrics
KIDS
21.92
-0.56
-2.48%
OrthoPediatrics
US · KIDS
#3642 by market cap
Listed 2017
21.92
-0.56
-2.48%
Live - 5344 symbols - heartbeat 69s ago
· 2026-10-08 10:02
After-hours
22.26
-0.98%
- Market cap
- 572.39M
- P/E (TTM)i
- -13.05
- P/Bi
- 1.67
- EPSi
- -1.69
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on KIDS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.13, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +15.45% YoY
Margins
- Gross margin
- 73.05%
- Operating margin
- -12.27%
- Net margin
- -16.78%
Key ratios & quality
- Enterprise valuei
- 611.53M
- Altman Z-Scorei
- 2.13
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 57.56M | 72.55M | 71.08M | 98.05M | 122.29M | 148.73M | 204.73M | 236.35M |
| Gross profit | 42.68M | 54.62M | 55.03M | 73.40M | 90.66M | 111.25M | 148.60M | 172.66M |
| Selling & admin expenses | 47.50M | 57.95M | 70.17M | 85.73M | 104.00M | 126.12M | 167.09M | 192.56M |
| Research & development | 4.73M | 5.75M | 5.27M | 5.54M | 8.45M | 10.90M | 11.03M | 9.10M |
| Operating profit | -9.55M | -9.08M | -20.41M | -17.87M | -21.79M | -25.77M | -29.52M | -29.00M |
| Pretax profit | -12.03M | -12.69M | -33.67M | -17.39M | -3.69M | -21.31M | -41.93M | -39.19M |
| Tax | 0 | 0 | -723.00K | -1.13M | -4.95M | -338.00K | -4.11M | 460.00K |
| Net profit | -12.03M | -13.73M | -32.94M | -16.26M | 1.26M | -20.97M | -37.82M | -39.65M |
| Basic EPS | -1 | -1 | -2 | -1 | 0 | -1 | -2 | -2 |
| Diluted EPS | -0.96 | -0.94 | -1.82 | -0.84 | 0.06 | -0.92 | -1.64 | -1.69 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 52.41M | 61.08M | 61.25M | 61.61M | 59.36M | 70.51M |
| Gross profit | 38.26M | 44.02M | 45.27M | 45.11M | 43.39M | 52.37M |
| Selling & admin expenses | 46.85M | 49.55M | 47.81M | 48.35M | 49.49M | 54.11M |
| Research & development | 2.35M | 2.16M | 2.33M | 2.26M | 2.23M | 2.33M |
| Operating profit | -10.94M | -7.69M | -4.87M | -5.51M | -8.34M | -4.07M |
| Pretax profit | -10.46M | -7.06M | -11.90M | -9.76M | -10.86M | -6.93M |
| Tax | 196.00K | 49.00K | -125.00K | 340.00K | -171.00K | 234.00K |
| Net profit | -10.66M | -7.11M | -11.77M | -10.10M | -10.69M | -7.16M |
| Basic EPS | 0 | 0 | -1 | 0 | 0 | 0 |
| Diluted EPS | -0.46 | -0.30 | -0.50 | -0.43 | -0.45 | -0.30 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 97.16M | 128.06M | 158.43M | 133.65M | 226.72M | 226.50M | 237.17M | 256.42M |
| Cash & ST investments | 60.69M | 70.78M | 83.90M | 53.54M | 118.29M | 80.31M | 68.83M | 60.85M |
| Inventory | 25.71M | 38.00M | 52.99M | 57.57M | 78.19M | 105.85M | 117.01M | 133.79M |
| Total assets | 112.11M | 182.15M | 320.41M | 304.27M | 427.73M | 438.75M | 473.21M | 508.63M |
| Total current liabilities | 9.22M | 13.66M | 35.03M | 29.72M | 30.87M | 41.67M | 33.96M | 46.20M |
| Short-term debt | 118.00K | 124.00K | 131.00K | 137.00K | 144.00K | 152.00K | 160.00K | 170.00K |
| Long-term debt | 21.16M | 26.07M | 1.04M | 907.00K | 763.00K | 9.91M | 72.96M | 99.82M |
| Total liabilities | 30,373,000.00 | 39,793,000.00 | 85,644,000.00 | 78,905,000.00 | 49,079,000.00 | 61,720,000.00 | 118,643,000.00 | 162,034,000.00 |
| Total equity | 81.73M | 142.36M | 234.77M | 225.37M | 378.65M | 377.03M | 354.57M | 346.60M |
| Retained earnings | -115.09M | -128.82M | -161.77M | -178.03M | -176.77M | -197.74M | -235.56M | -275.21M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 232.06M | 257.70M | 245.85M | 256.42M | 245.87M | 252.51M |
| Cash & ST investments | 58.77M | 70.15M | 57.73M | 60.85M | 48.81M | 45.88M |
| Inventory | 119.75M | 125.27M | 128.81M | 133.79M | 134.02M | 137.57M |
| Total assets | 470.25M | 503.61M | 493.49M | 508.63M | 502.19M | 511.39M |
| Total current liabilities | 37.51M | 38.67M | 33.23M | 46.20M | 47.18M | 52.85M |
| Short-term debt | 162.00K | 164.00K | 166.00K | 170.00K | 172.00K | 172.00K |
| Long-term debt | 73.03M | 97.00M | 99.17M | 99.82M | 100.39M | 99.46M |
| Total liabilities | 123,104,000.00 | 148,092,000.00 | 144,177,000.00 | 162,034,000.00 | 163,478,000.00 | 167,774,000.00 |
| Total equity | 347.15M | 355.51M | 349.31M | 346.60M | 338.71M | 343.61M |
| Retained earnings | -246.22M | -253.34M | -265.11M | -275.21M | -285.90M | -293.06M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -15.58M | -17.77M | -18.53M | -13.06M | -21.77M | -27.05M | -27.05M | -4.85M |
| Depreciation & amortization | 2.89M | 4.67M | 8.01M | 10.68M | 13.10M | 17.39M | 19.08M | 21.12M |
| Free cash flow | -21.05M | -29.86M | -29.83M | -29.07M | -31.80M | -43.92M | -41.31M | -15.96M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 43.43M | 60.00M | 70.21M | 0 | 139.28M | -- | -- | -- |
| Ending cash balance | 60.69M | 72.03M | 30.13M | 9.01M | 10.46M | 33.03M | 45.78M | 21.62M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -4.16M | -10.46M | -581.00K | 10.35M | -3.29M | 928.00K |
| Depreciation & amortization | 5.05M | 5.17M | 5.30M | 5.60M | 5.72M | 5.71M |
| Free cash flow | -8.38M | -13.91M | -3.42M | 9.75M | -5.05M | -3.12M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 35.43M | 46.61M | 18.88M | 21.62M | 14.25M | 19.06M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -18.61 | -12.25 | -17.47 | -7.07 | 0.42 | -5.55 | -10.34 | -11.31 |
| ROA %i | -12.37 | -8.95 | -12.79 | -5.21 | 0.34 | -4.84 | -8.29 | -8.08 |
| ROIC %i | -11.11 | -7.51 | -14.64 | -6.12 | 1.05 | -5.47 | -9.28 | -9.07 |
| 5-year avg ROE %i | -- | -- | -- | -- | -11.00 | -8.39 | -8.00 | -6.77 |
| EBIT margin %i | -16.97 | -12.61 | -42.57 | -15.44 | -1.03 | -17.32 | -14.42 | -12.27 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 10.54 | 9.37 | 4.52 | 4.50 | 7.34 | 5.44 | 6.98 | 5.55 |
| Quick ratioi | 7.62 | 6.39 | 2.90 | 2.41 | 4.64 | 2.76 | 3.27 | 2.48 |
| Debt / assetsi | 18.98 | 14.38 | 0.37 | 0.34 | 0.21 | 2.29 | 15.45 | 19.66 |
| LT debt / equityi | 25.88 | 18.31 | 0.44 | 0.40 | 0.20 | 2.63 | 20.58 | 28.80 |
| Interest coveragei | -4.33 | -2.59 | -8.87 | -6.74 | -0.52 | -- | -- | -- |
| Revenue CAGR (3Y) %i | 22.90 | 24.83 | 15.93 | 19.43 | 19.01 | 27.91 | 27.81 | 24.56 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -11.33 | -11.49 | -12.67 | -11.31 | -11.57 | -11.36 |
| ROA %i | -8.97 | -8.94 | -9.28 | -8.08 | -8.16 | -7.83 |
| ROIC %i | -10.15 | -10.02 | -10.22 | -9.07 | -9.23 | -8.87 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -13.72 | -13.28 | -13.48 | -12.27 | -11.68 | -10.63 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.19 | 6.66 | 7.40 | 5.55 | 5.21 | 4.78 |
| Quick ratioi | 2.74 | 3.21 | 3.28 | 2.48 | 2.19 | 2.02 |
| Debt / assetsi | 15.56 | 19.29 | 20.13 | 19.66 | 20.02 | 19.48 |
| LT debt / equityi | 21.04 | 27.29 | 28.39 | 28.80 | 29.64 | 28.94 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Trauma and deformity is the largest reported line at 74.65% of revenue, across 3 reported segments.
- The next-largest line, Scoliosis, is a distant second at 23.93% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Trauma and deformity74.65%
Scoliosis23.93%
Sports medicine/other1.42%
Quote time 2026-10-08 10:02:57 · For reference only, not investment advice and not tailored to your situation.